VOSEVI is the First Once-Daily, Single Tablet HCV Regimen for Re-Treatment, and Completes Gilead's Portfolio of Sofosbuvir-Based HCV Direct-Acting Antiviral Treatments
MISSISSAUGA, ON, Aug. 17, 2017 /CNW/ - Gilead Sciences Canada, Inc. (Gilead Canada) today announced that Health Canada has granted a Notice of Compliance for VOSEVI™ (sofosbuvir 400 mg/velpatasvir 100 mg/voxilaprevir 100 mg) tablets, a pan-genotypic single-tablet regimen for the treatment o
MAVIRET is the first and only 8-week, pan-genotypic treatment for hepatitis C patients without cirrhosis and who are new to treatment*1
The approval is supported by a 97 percent (n=639/657) cure** rate across GT1-6 patients without cirrhosis and who are new to treatment2
MAVIRET is the only pan-genotypic treatment approved for use in patients across all stages of chronic kidney disease
MONTREAL, Aug. 17, 2017 /CNW/ - AbbVie (NYSE: ABBV), a glo...
Hepatocellular carcinoma (HCC), which has an annual incidence rate of 1%-4%, is a potential complication of hepatitis C virus (HCV) cirrhosis owing to a multistep carcinogenesis pathway. Previous HCV treatment with interferon was associated with poor cure rates and was limited to individuals with early fibrosis or well-compensated cirrhosis. Such therapy, however, also led to a decrease in HCC after a sustained viral response (SVR). Although remarkable pro
Treatment of hepatitis C virus (HCV) with sofosbuvir-based direct acting antivirals (DAAs) was recently found as effective and well-tolerated in elderly patients as it was in younger patients in previous development trials.
"Historically, older patients have been underrepresented in studies evaluating the efficacy and safety of HCV treatment due to poor tolerability and suboptimal response to interferon-based regimens," the researchers wrote.
Satapathy
Steatosis is an independent risk factor for fibrosis in African-Americans with chronic HCV infection.
A study recently published in Digestive Disease Science found that hypertension, older age, obesity, and HIV are risk factors and that steatosis is an independent risk factor for liver fibrosis in African-Americans with chronic hepatitis C.
"Our retrospective study showed that there are risk factors, such as HIV coinfection for progression of liver fib
Patients with HCV infection have a higher risk for carotid atherosclerosis and cerebrocardiovascular events.
Hepatitis C virus (HCV) infection is a common cause of chronic liver disease worldwide and is associated with greater mortality compared with that in the general population or even mortality associated with HIV infection. Although liver disease and liver cirrhosis account for the bulk of HCV-related disease burden and deaths, it is becoming increas
Friday, August 11, 2017
Research & Discoveries
Melbourne scientists are creating mini-livers in a dish
MELBOURNE scientists are creating mini livers in a dish using a world-first combination of human cells in an ambitious bid to grow liver tissue for transplants. The tiny experimental organs – developed from cells donated by cancer patients – will be used to test drugs and eventually treat disease.
Routine hospital tool found to predict poor ...
MELBOURNE scientists are creating mini livers in a dish using a world-first combination of human cells in an ambitious bid to grow liver tissue for transplants.
The tiny experimental organs — developed from cells donated by cancer patients — will be used to test drugs and eventually treat disease. The O’Brien Institute department of St Vincent’s Institute and St Vincent’s Hospital team has grown liver organoids that are just a few millimetres long.
...
Findings of research led by Cedars-Sinai may help pinpoint liver transplant recipients at risk for early disability and prolonged hospitalization
LOS ANGELES (Aug. 10, 2017) -- A routinely used hospital tool can predict which liver transplant recipients are more likely to do poorly after surgery, according to a study led by Cedars-Sinai. The findings could help doctors identify which patients should receive physical therapy or other targeted interventions
UK health officials are putting a temporary limit on who can have a hepatitis B vaccination because stocks are running low.
The move is in response to the wider, global shortage of the jab caused by manufacturing issues.
UK travellers are being told they may not be able to get it before they leave Britain for higher-risk countries.
Babies and high-risk groups will be prioritised under the measures that are expected to continue into 2018.
A spokes
